Blocking MEK prevents T cell burnout and extends cancer immunotherapy persistence

T cell exhaustion is a metabolic collapse: these specialized immune killers burn through their ATP supply manufacturing cytotoxic proteins to destroy cancer cells until their energy reserves deplete and they surrender. Researchers have now identified MEK, a signaling molecule, as the regulator of this activity-versus-conservation balance: while full MEK activation keeps T cells at maximum power but risks terminal burnout, MEK inhibition reduces nutrient demand and mitochondrial NADH accumulation, allowing T cells to persist longer while producing tumor-killing proteins at a sustainable pace. In chronic TCR stimulation models, MEK inhibition reverses mitochondrial dysfunction and preserves transcription of memory-associated genes while suppressing terminal exhaustion markers. The practical implication is direct: for large tumors or patients with limited immune capacity, a metabolically conservative "slow burn" of T cells outperforms aggressive attacks that ignite and collapse rapidly. This opens a selective therapeutic pathway where MEK inhibitors function not as cell weakeners but as persistence multipliers.